1292822-17-3

Upstream product

• 1292822-16-2 (S)-3-[(4-methoxybenzyl)thio]-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide 
• 70-11-1 α-bromoacetophenone 
• 3789-59-1 (R)-1-phenylpropylamine 

Downstream Products

• 930577-43-8 3-ethylsulfinyl-2-phenyl-N-((S)-1-phenyl-propyl)-quinoline-4-carboxamide 
• 1292822-01-5 C₂₈H₂₈N₂O₂S 
• 1292822-02-6 C₂₉H₂₉N₃O₃S 
• 1061198-04-6 C₂₆H₂₄N₂O₂S 
• 1061198-02-4 C₂₆H₂₄N₂O₂S 
• 930577-42-7 3-ethylthio-2-phenyl-N-((S)-1-phenylpropyl)-quinoline-4-carboxamide 
• 930577-39-2 3-methylthio-2-phenyl-N-((S)-1-phenylpropyl)-quinoline-4-carboxamide 

Relevant academic research and scientific papers

Development of novel NK3 receptor antagonists with reduced environmental impact

The neurokinin B (NKB)–neurokinin-3 receptor (NK3R) signaling positively regulates the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. The NK3R-selective antagonists may suppress the reproductive functions of mammals. For developme

NOVEL COMPOUND, AGENT AND NK3 RECEPTOR ANTAGONIST

PROBLEM TO BE SOLVED: To provide a NK3 receptor antagonist that inhibits the propagation of animals without adverse effect on an ecological system. SOLUTION: The present invention provides a compound represented by formula (I') (R1 is H, a hydroxy group or the like; R2 is a hydroxy group, a mercapto group or the like; R3 is a phenyl group or naphthyl group). SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists

The neurokinin-3 (NK3) receptor is regarded as a potential novel target for treating patients with schizophrenia. Herein we report the synthesis and SAR of a series of C3-alkylsulfoxide substituted quinolines as potent NK3 receptor antagonists. These compounds have excellent NK3 functional activity, good selectivity and drug-like properties. Several key compounds have good in vitro/in vivo DMPK characteristics, and are active in a gerbil locomotor activity model.